Shamburg News · 8-K filed Oct 16, 2026, 5:15 PM EDT

DataMeds AI Enters IP License with REBOOT Health AI; Regains Nasdaq Equity Compliance Claim

MEDS · DataMeds AI, Inc.

  • Material agreement
  • Delisting
  • Financing
  • Other
  • Materiality: high

On October 13, 2026, DataMeds AI entered into an IP License and Product and Services Agreement with REBOOT Health AI, granting an exclusive U.S. license within a GLP-1 direct-to-consumer field of use in exchange for 666,667 common shares and a $50,000 payment toward reconfiguration work. The company also disclosed a April 13, 2026 Nasdaq deficiency letter citing stockholders' equity of $(12,447,801), and states it believes it now exceeds the $2,500,000 minimum following recent equity transactions, while awaiting Nasdaq confirmation.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 1.01, 3.01, 3.02, accession 0001493152-26-047451.

Written from the filing by Shamburg Markets. Figures are as reported by the company.